Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

B Glintborg; T Kringelbach; N Bolstad; D J Warren; G Eng; I J Sørensen; A G Loft; O Hendricks; I Hansen; A Linauskas; H Nordin; S Kristensen; H Lindegaard; D V Jensen; G L Goll; E Høgdall; J Gehin; C Enevold; C H Nielsen; N S Krogh; J S Johansen; M L Hetland

doi:10.1080/03009742.2017.1376110

Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

B Glintborg, T Kringelbach, N Bolstad, D J Warren, G Eng, I J Sørensen, A G Loft, O Hendricks, I Hansen, A Linauskas, H Nordin, S Kristensen, H Lindegaard, D V Jensen, G L Goll, E Høgdall, J Gehin, C Enevold, C H Nielsen, N S KroghJ S Johansen, M L Hetland

8 Citations (Scopus)

Original language	English
Journal	Scandinavian Journal of Rheumatology
Volume	47
Issue number	5
Pages (from-to)	418-421
Number of pages	4
ISSN	0300-9742
DOIs	https://doi.org/10.1080/03009742.2017.1376110
Publication status	Published - Sept 2018

Access to Document

10.1080/03009742.2017.1376110

Cite this

Glintborg, B., Kringelbach, T., Bolstad, N., Warren, D. J., Eng, G., Sørensen, I. J., Loft, A. G., Hendricks, O., Hansen, I., Linauskas, A., Nordin, H., Kristensen, S., Lindegaard, H., Jensen, D. V., Goll, G. L., Høgdall, E., Gehin, J., Enevold, C., Nielsen, C. H., ... Hetland, M. L. (2018). Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. Scandinavian Journal of Rheumatology, 47(5), 418-421. https://doi.org/10.1080/03009742.2017.1376110

Glintborg, B, Kringelbach, T, Bolstad, N, Warren, DJ, Eng, G, Sørensen, IJ, Loft, AG, Hendricks, O, Hansen, I, Linauskas, A, Nordin, H, Kristensen, S, Lindegaard, H, Jensen, DV, Goll, GL, Høgdall, E, Gehin, J, Enevold, C, Nielsen, CH, Krogh, NS, Johansen, JS & Hetland, ML 2018, 'Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care', Scandinavian Journal of Rheumatology, vol. 47, no. 5, pp. 418-421. https://doi.org/10.1080/03009742.2017.1376110

@article{bd0cf35a71db483b9e34d77f5d3f58c2,

title = "Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care",

author = "B Glintborg and T Kringelbach and N Bolstad and Warren, {D J} and G Eng and S{\o}rensen, {I J} and Loft, {A G} and O Hendricks and I Hansen and A Linauskas and H Nordin and S Kristensen and H Lindegaard and Jensen, {D V} and Goll, {G L} and E H{\o}gdall and J Gehin and C Enevold and Nielsen, {C H} and Krogh, {N S} and Johansen, {J S} and Hetland, {M L}",

note = "COPECARE",

year = "2018",

month = sep,

doi = "10.1080/03009742.2017.1376110",

language = "English",

volume = "47",

pages = "418--421",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

AU - Glintborg, B

AU - Kringelbach, T

AU - Bolstad, N

AU - Warren, D J

AU - Eng, G

AU - Sørensen, I J

AU - Loft, A G

AU - Hendricks, O

AU - Hansen, I

AU - Linauskas, A

AU - Nordin, H

AU - Kristensen, S

AU - Lindegaard, H

AU - Jensen, D V

AU - Goll, G L

AU - Høgdall, E

AU - Gehin, J

AU - Enevold, C

AU - Nielsen, C H

AU - Krogh, N S

AU - Johansen, J S

AU - Hetland, M L

N1 - COPECARE

PY - 2018/9

Y1 - 2018/9

U2 - 10.1080/03009742.2017.1376110

DO - 10.1080/03009742.2017.1376110

M3 - Letter

C2 - 29310493

SN - 0300-9742

VL - 47

SP - 418

EP - 421

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

IS - 5

ER -